The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a huge mover today! About 1.45M shares traded hands or 29.46% up from the average. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 6.93% since April 4, 2016 and is downtrending. It has underperformed by 8.02% the S&P500.
The move comes after 5 months positive chart setup for the $14.09B company. It was reported on Nov, 4 by Barchart.com. We have $111.10 PT which if reached, will make NASDAQ:BMRN worth $5.07B more.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage
Out of 15 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 13 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 87% are positive. BioMarin Pharmaceutical has been the topic of 34 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by RBC Capital Markets given on Monday, August 24. As per Wednesday, November 18, the company rating was initiated by Goldman Sachs. The firm has “Buy” rating given on Tuesday, August 25 by Cowen & Co. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Overweight” rating given on Friday, August 5 by Piper Jaffray. The rating was initiated by BMO Capital Markets on Thursday, April 7 with “Outperform”. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Tuesday, February 16 by Stifel Nicolaus. The stock has “Buy” rating given by Deutsche Bank on Thursday, November 3. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, February 26 report. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Outperform”. On Wednesday, August 5 the stock rating was maintained by Wedbush with “Hold”.
According to Zacks Investment Research, “BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin’s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.”
Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.10, from 1.18 in 2016Q1. The ratio is positive, as 34 funds sold all BioMarin Pharmaceutical Inc. shares owned while 104 reduced positions. 37 funds bought stakes while 140 increased positions. They now own 153.99 million shares or 5.12% less from 162.30 million shares in 2016Q1.
Fort Washington Invest Oh has 9,350 shares for 0.01% of their US portfolio. Eqis Capital Mgmt last reported 26,912 shares in the company. The Massachusetts-based Tekla Capital Mgmt Lc has invested 2.08% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Partner Inv Management Lp accumulated 1.5% or 11,752 shares. Deutsche Bancorp Ag has 1.38M shares for 0.08% of their US portfolio. Commerzbank Aktiengesellschaft Fi holds 0.09% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 177,243 shares. Automobile Association accumulated 0.01% or 29,407 shares. Moreover, Pnc Financial Service Group Inc has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 47,161 shares. Profund Advsr Lc, a Maryland-based fund reported 95,252 shares. Moreover, Oregon Employees Retirement Fund has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 7,200 shares. Livforsakringsbolaget Skandia Omsesidigt holds 0.04% or 12,020 shares in its portfolio. Moreover, Scout Invs has 0.27% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 126,036 shares. Lazard Asset Mngmt Ltd Com accumulated 35,554 shares or 0.01% of the stock. Edgewood Ltd Liability reported 5,000 shares or 0% of all its holdings. Jefferies Group Limited Co accumulated 25,994 shares or 0.01% of the stock.
Insider Transactions: Since May 5, 2016, the stock had 0 buys, and 21 insider sales for $58.33 million net activity. BAFFI ROBERT sold 5,000 shares worth $435,249. BIENAIME JEAN JACQUES sold 41,666 shares worth $3.52 million. The insider SPIEGELMAN DANIEL K sold 1,649 shares worth $146,992. Shares for $1.43M were sold by FUCHS HENRY J on Friday, August 26. Ajer Jeffrey Robert also sold $1.77 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. On Wednesday, July 27 LAWLIS V BRYAN sold $104,927 worth of the stock or 1,100 shares. Another trade for 2,167 shares valued at $216,700 was sold by Davis George Eric.
More news for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were recently published by: Gurufocus.com, which released: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $5.6 million …” on October 18, 2016. Forbes.com‘s article titled: “BioMarin Pharmaceutical Enters Oversold Territory (BMRN)” and published on October 14, 2016 is yet another important article.
BMRN Company Profile
BioMarin Pharmaceutical Inc. (BioMarin), incorporated on October 25, 1996, develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and in other countries. Naglazyme received marketing approval in the United States, the European Union and in other countries. Kuvan was granted marketing approval in the United States and the European Union. Aldurazyme was approved for marketing in the United States, the European Union and in other countries. Firdapse received marketing approval in the European Union.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.